| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
|
J Virol
|
1996
|
4.29
|
|
2
|
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.
|
Proc Natl Acad Sci U S A
|
2000
|
2.20
|
|
3
|
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.
|
J Infect Dis
|
1999
|
2.03
|
|
4
|
The development of erectile dysfunction in men treated for prostate cancer.
|
J Urol
|
2001
|
1.97
|
|
5
|
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
|
J Natl Cancer Inst
|
1999
|
1.61
|
|
6
|
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
|
J Clin Oncol
|
1993
|
1.46
|
|
7
|
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
|
Cancer Invest
|
1998
|
1.39
|
|
8
|
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
|
Blood
|
1998
|
1.35
|
|
9
|
Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment.
|
Cancer Res
|
1993
|
1.34
|
|
10
|
Alterations in T cell receptor and signal transduction molecules in melanoma patients.
|
Clin Cancer Res
|
1995
|
1.33
|
|
11
|
Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples.
|
J Clin Microbiol
|
1999
|
1.25
|
|
12
|
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
|
Cancer Res
|
1996
|
1.21
|
|
13
|
Dual control of LIF expression and LIF receptor function regulate Stat3 activation at the onset of uterine receptivity and embryo implantation.
|
Proc Natl Acad Sci U S A
|
2001
|
1.21
|
|
14
|
HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study.
|
J Acquir Immune Defic Syndr
|
1994
|
1.14
|
|
15
|
Interspecific backcross mice show sex-specific differences in allelic inheritance.
|
Genetics
|
1991
|
1.13
|
|
16
|
Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans.
|
J Infect Dis
|
1995
|
1.13
|
|
17
|
Effects of subtle changes in the SU protein of ecotropic murine leukemia virus on its brain capillary endothelial cell tropism and interference properties.
|
Virology
|
1996
|
1.12
|
|
18
|
Interleukin 1 alpha increases serum leptin concentrations in humans.
|
J Clin Endocrinol Metab
|
1997
|
1.12
|
|
19
|
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy.
|
Infect Immun
|
1998
|
1.10
|
|
20
|
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
|
J Clin Oncol
|
1990
|
1.06
|
|
21
|
Fibrinogen induces IL-8 synthesis in human neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine or leukotriene B(4).
|
J Immunol
|
2001
|
1.05
|
|
22
|
Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature.
|
Can J Neurol Sci
|
1991
|
1.00
|
|
23
|
Alteration of Met protooncogene product expression and prognosis in breast carcinomas.
|
Anal Quant Cytol Histol
|
1999
|
0.90
|
|
24
|
T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
|
J Immunol
|
1998
|
0.90
|
|
25
|
A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
|
AIDS Res Hum Retroviruses
|
2001
|
0.89
|
|
26
|
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
|
N Engl J Med
|
1993
|
0.89
|
|
27
|
Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine.
|
Cancer Res
|
1999
|
0.89
|
|
28
|
Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
|
Cancer Res
|
1992
|
0.89
|
|
29
|
Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.
|
J Immunother Emphasis Tumor Immunol
|
1993
|
0.89
|
|
30
|
Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers.
|
Cancer Epidemiol Biomarkers Prev
|
2000
|
0.87
|
|
31
|
Dose-related immunologic effects of levamisole in patients with cancer.
|
J Clin Oncol
|
1993
|
0.87
|
|
32
|
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
|
J Clin Oncol
|
1998
|
0.86
|
|
33
|
Conditioned immune response to interferon-gamma in humans.
|
Clin Immunol
|
1999
|
0.85
|
|
34
|
Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery.
|
Blood
|
1990
|
0.83
|
|
35
|
Inhibition of Friend virus replication by a compound that reacts with the nucleocapsid zinc finger: anti-retroviral effect demonstrated in vivo.
|
Virology
|
1998
|
0.82
|
|
36
|
Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
|
Cancer J Sci Am
|
2000
|
0.82
|
|
37
|
Expressions of hepatic genes, especially IGF-binding protein-1, correlating with serum corticosterone in microarray analysis.
|
J Mol Endocrinol
|
2004
|
0.82
|
|
38
|
Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
|
AIDS
|
2000
|
0.81
|
|
39
|
Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.
|
Clin Cancer Res
|
1996
|
0.81
|
|
40
|
Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.
|
Proc Natl Acad Sci U S A
|
1998
|
0.80
|
|
41
|
Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
|
Blood
|
1997
|
0.80
|
|
42
|
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
|
J Natl Cancer Inst
|
1996
|
0.79
|
|
43
|
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
|
J Cancer Res Clin Oncol
|
1998
|
0.77
|
|
44
|
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
|
Clin Immunol
|
1999
|
0.76
|
|
45
|
Alkylation of DNA in rats by N-nitrosomethyl-(2-hydroxyethyl)amine: dose response and persistence of the alkylated lesions in vivo.
|
Cancer Res
|
1988
|
0.76
|
|
46
|
Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.
|
J Natl Cancer Inst
|
1991
|
0.75
|
|
47
|
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer.
|
J Immunother Emphasis Tumor Immunol
|
1996
|
0.75
|
|
48
|
Levamisole-induced neopterin synthesis.
|
Ann N Y Acad Sci
|
1993
|
0.75
|
|
49
|
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.
|
Blood
|
1991
|
0.75
|
|
50
|
Stress factors and breast cancer outcome.
|
J Clin Oncol
|
1987
|
0.75
|
|
51
|
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
|
J Immunother Emphasis Tumor Immunol
|
1996
|
0.75
|
|
52
|
1,3-Dialkyltriazenes: reactive intermediates and DNA alkylation.
|
Chem Res Toxicol
|
1991
|
0.75
|